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Abstract
Action of poly-[(trans-l,2-diaminocyclohexane)platinum]-carboxyamylose (poly-plat) and
cisplatin (CDDP) on the immune system was studied using isolated peritoneal macrophages and
compared with liver resident macrophages from normal, CDDP and poly-plat [10 mg/kg] treated
Swiss Webster mice for 2-12 days. Peritoneal macrophages were treated [10 mg/L] for 2 h and
allowed to grow in normal medium at 37C (5% CO2) for 24 h. Similarly macrophages from Swiss
Webster mice treated with CDDP and poly-plat were isolated and cultured on normal medium.
Supernatants from cells in culture were collected at 0.5, 1, 2, and 24 h post-treatment for various
cytolytic factors. CDDP and poly-plat treatments induce an activation of the peritoneal
macrophages and the Kupffer cells through cell growth, development of cytoplasmic extensions,
enhanced number of lysosomes and the activity of various cytolytic factors. Poly-plat treatment of
the macrophages induces a 500 fold increase in the number of lysosomes, compared to CDDP
treatment where there was only a 50 fold increase.
"POLY-PLAT"
Po ly-[( trans-1,2-diam nocyclohexane plat num]-carboxyamylose
Introduction
Cisplatin (cis-diaminedichloroplatinum II) (CDDP) is a broad spectrum antineoplastic agent
currently used to treat a variety of cancers (1). it has been demostrated to inhibit DNA replication
(2) It has also been shown to and transcription through intrastrand and interstrand crosslinking
inhibit cytokinesis in cases where the DNA has already replicated through the depolymerization of
actin-like microfilaments. Cisplatin has also been shown to enhance specific cellular immune
responses in tumor bearing mice (3), through activation of murine peritoneal macrophages (4,5).
Such activated macrophages in culture have been found to destroy tumor cells through the
production of various cvtolytic factors like interleukin-lo (IL-lo0, tumor necrosis factor-o (TNF-00
(5) and nitric oxide (NO) However, it suffers from dose limiting side effects ranging from vomiting,
diarrhea, neurotoxicity, nephrotoxicity, and embryotoxicity. These toxicities can be ameliorated
through the hydration of patients, by the use of compounds rich in thiols, or the administration of
vitamin D New compounds with differeing ligand are being synthesized in order to increase the
efficacy and reduce the toxicities due to cisplatin. Poly-plat (poly-[(trans-l,2-diaminocyclohexane)
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platinum]-carboxyamylose) is one such compound that has been shown to be more effective in
activating macrophages in culture and destroying the target tumor cells through an interaction
using lysosomes and various cytolytic factors.
In order to study the effects of poly-plat on the activation of resident tissue macrophages,
Kupffer cells comprising the largest population of any fixed tissue macrophage in the body (8/were
studied and compared after cisplatin and poly-plat treatments. Morphological characteristics were
used to determine Kupffer cell number and size, and these data were compared with light
microscopic studies in order to obtain a better understating of both cisplatin’s and "Poly-plat’s"
effects on the Kupffer cell population. Mouse peritoneal macrophages were also used in culture in
order to study the release of cytokines from activated macrophages.
Materials and Methods
Swiss webster mice (Charles River Laboratories, MA) were sacrificed by cervical
dislocation and peritoneal macrophages were isolated according to procedures described earlier
Aspirated cells were seeded onto 18 mm glass coverslips, placed in 35 mm petri dishes, at 2-4 x
106 cells/ml and incubated for 2 h at 37C. Cells were washed vigorously to remove non-adherent
cells. Cell cultures were incubated in normal medium (minimal essential media and 10% heat
inactivated fetal calf serum) at 37C in a 5% CO2 incubator. Sarcoma 180 ascites ($180; CCRFS-
18011; American Type Culture Collection, MD) served as target cells for macrophages. Normal
hepatocytes, obtained by mincing a small piece of liver through a fine wire mesh, 105 x 105 #m in
size (Tetko, Inc., IL), also served as target cells for the macrophages. An effector target cell ratio
of 1"10 was maintained in all experiments. Isolated macrophages were treated with poly-plat (5
l.tg/ml) in 0.85% NaCI for 2 h. The drug containing medium was replaced by normal medium and
supernatant (500 #1) was collected at 0.5, 1, 2, and 24 h for cytolytic factor analysis. In addition,
macrophages were also treated with cisplatin [5 #g/ml dissolved in physiological saline.
Untreated cells in normal medium served as controls. For in vivo studies mice (20 g) were injected
(ip) with CDDP or poly-plat (10 mg/kg). Mice were sacrificed after 2 or 12 days and peritoneal
macrophages were isolated as described above. After 2 h in the culture medium supernatants were
analyzed for various cytolytic factors.
Lysosomal assay. The quantification of lysosomes before and after various treatments
was achieved by exposing macropha,g,e cultures to fresh medium containing acridine orange (5
l.tg/ml) for 30 min. at 37C in the dark ’’. After careful washing macrophages were examined under
Zeiss 10 Laser Scanning Confocal Microscope.
TNF-o assay. TNF-o released from supernatants of the macrophages was assayed
using specific analysis kits (Genzyme; Cambridge, MA). The multiple antibody sandwich I,rj,ociple
was utilized with a murine monoclonal antibody specific for murine "I’NF-o in the samples"’J. An
HRP-conjugated anti-murine TNF-o antibody was used to bind the multiple epitopes on TNF-o. A
substrate solution was then added resulting in a color change. The reaction was stopped by
acidification and absorbance was read at 450 nm. Standard curves were generated with TNF-o
(35-2240 pg/ml) provided in the kits and linear regression analysis was performed.
IL-lo assay. IL-I was assayed using ELI
kits (Genzyme; Cambridge, MA) The
method used the multiple antibody sandwich principl= where monoclonal anti-murine iL-lo
was used to bind murine IL-l(z present in the supernatant. A biotinylated polyclonal antibody
binding the IL-lo was added and unbound material was washed out. Peroxidase-conjugated avidin
was used to bind these biotin tagged complexes. A substrate solution was then added resulting in
a color change. The reaction was stopped by acidification and absorbance was read at 450 nm.
Standard curves were generated with IL-lc (15-405 pg/ml) provided in the kits and linear
regression analysis was performed.
Inducible Nitric Oxide Synthase (iNOS) Staining. Macrophage monolayers were stained for
the inducible enzyme which catalyze,lhe oxidation of L-arginine to citrulline and NO using avidin-
biotin-peroxidase complex method ’ iNOS was confirmed by VECTASTAIN elite ABC Kit
(Vector Laboratories, Inc., Burlingame, (A).
Nitrite Assay for Estimation of Nitric Oxide Production. The concentration of stable nitrite,
end product Irom nitric oxide generation by effector macrophages, was determined by the method
of Ding et al 12/based on Greiss reaction. Briefly, 100 #1 of supernatant from untreated and treated
macrophages collected at various times were mixed with equal volume of Greiss reagent (1%
sulfanilamide, 5% phosphoric acid, 0.1% naphthylethylenediamine dihydrochloride; Sigma, MO).
The mixtures were incubated for 10 min. at room temperature and the absorbance read at 540 nm.
Standard curves were generated using nM-220 #M NaNO and nitrite concentrations were
determined using linear regression analysis.
For Kupffer cell studies Swiss Webster mice and Wistar rats (Charles Rivers Laboratories,
Wilmington MA) were treated with an intraperitoneal injection of either cisplatin (1.8 mg/kg) or poly-
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plat (2 mg/kg) for five consecutive days. On day six animals were killed and liver was excised and
freeze sectioned. Sections were fixed in 1% glutaraldehyde, 5% sucrose in 0.5M cacodylate
buffer, pH 7.2, for 30-60 seconds at 4 C. Following fixation, the coverslips were washed and
stained for nonspecific esterase activity, the population of macrophages in each of the sections
was were quantitatively rated based on the number of stained macrophages present within the
tissue. These cells were counted per unit area using the same magnification with each section.
For electron microscopy studies variously treated animal liver was perfused with normal
saline for one minute, followed by a fifteen minute perfusion fixation with 2% paraformaldehyde in
phosphate buffer. The periportal region was excised diced into mm segments and washed in
cold PBS. The tissues were then post-fixed in 1% OsO4 in PBS (pH 7.3) for 60 minutes at 4 C,
followed by three washings in 0.1 M sodium acetate. The tissues were then washed in a graded
acetone series and embedded in araldite. The sectioning was performed on the LKB
Ultramicrotome and collected on copper mesh grids, which were then stained with uranyl acetate
and lead citrate. The tissues were viewed on the Phillips CM-10 TEM.
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Fig. 1: In vitro studies showing the IL-lo release in the supernatants of murine peritoneal
macrophages with either CDDP or poly-plat (5 pg/ml) after 30 min, 60 min, 2 h and 24 h post-
treatment. Note the large increases in IL-lo levels after 30 min reaching a maximum by 60
min. These levels are maintained for almost 24 h compared to CDDP where the increase is
gradual but still less than after poly-plat.
Results
Normal murine peritoneal macrophages, when treated with poly-plat for 2 h at 37C in
culture, developed extension formations within 2 h radiating from the cell body in all directions.
Such extension formation was also observed after cisplatin treatment but only after 24 h. When
these poly-plat treated macrophages were co-incubated with $180 tumor cells they immediately
established contact with several target cells and formed cytoplasmic continuity through which
lysosomes were transported into the tumor cells causing their lysis. CDDP treated cells developed
cytoplasmic extensions that were fewer in number and established contact with fewer tumor cells
when compared to poly-plat treated macrophages. Normal macrophages did not form cytoplasmic
extensions and, when co-incubated with $180 cells, failed to show any interaction for the times of
observation.
Lysosomal studies: Based on fluorescence measurements after acridine orange labeling,
we observed a 500-fold increase in the number of lysosomes in the macrophages after only 2 h of
poly-plat treatment compared to untreated macrophages. The lysosomes were plentiful in the
cytoplasm of the macrophages and in the drug-induced cytoplasmic extensions radiating from the
cell body. Comparatively, cisplatin treatment demonstrated only a 50-fold increase in the
lysosomes, both in the cell body and the cytoplasmic extensions. Poly-plat demonstrated very little
TNF-o activity, barely reaching 200 pg/ml at 24 h post-treatment.
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Cisplatin demonstrated the usual enhanced release of TNF-o at various time intervals, reaching a
peak value at 2 h post-treatment (3000 pg/ml).
Compared to cisplatin treatments there was an increase in IL-lo levels in the supernatants
of macrophages treated with poly-plat for up to 24 h of testing. The greatest increases were seen 2
h post-treatment (400-500 pg/ml) with a subsequent decrease from there on (Fig. 1). IL-lo levels
demonstrated a consistent increase after cisplatin treatment, reaching a maximum after 24 h. IL-
lo levels after poly-plat treatment demonstrated a decline after a peak at 2 h post-treatment but
these levels were still equal to or above those after cisplatin treatment, However, macrophages
isolated from ’poly-plat’ treated mice demonstrated a significantly higher level of IL-lo (500pg/ml)
than cisplatin treatment (250 pg/ml), but only after 12.days of the treatment (Fig. 2). Expression of
iNOS was visible in poly-plat treated cells while none was detected in untreated macrophages.
Only moderate levels of iNOS were visible in cisplatin treated macrophages. Increases in NO
levels were detected in cell culture supernatants from poly-plat treated cells at various times. The
increase was seen as early as 30 min of the treatment and persisted up to 24 h post-treatment.
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Fig. 2: In vivo studies showing the IL-lo release in the supernatants of the murine
peritoneal macrophages from CDDP or poly-plat (10 mg/kg) treated mice for 2 or 12 days. Note
the interleukin increase in poly-plat treated mice is twice that of CDDP treated animals but only
after 12 days.
Cisplatin treatment demonstrated an increase in Kupffer cell extensions. In the normal
liver Kupffer cells were round and exhibited few extensions. Poly-plat treatment, however,
revealed an even more pronounced activation with a greater increase in extension formation. The
normal liver exhibited a moderate amount of esterase staining. The cisplatin treated liver had an
increase in esterase staining in the sinusoids, and a significant decrease in the hepatocytes. Poly-
plat treatment disclosed a significantly higher degree of staining in the sinusoids than
cisplatin, and a moderate amount of staining in the hepatocytes, comparable to the normal liver.
Discussion
Stimulation of the immune system is a major function of many antineoplastic agents.
Cisplatin stimulates the immune system throu_clh macrophage activation making the macrophages
more efficient in phagocytosing tumor cells (131. The severe toxic side effects evident in cisplatin
treatment seem to be due to the disruption in sulphydryl containing enzymes, resulting in a
decrease in intercellular calcium (14). Poly-plat shows no such disruption, and as a result has been
shown to be much less toxic (15). Due to the decrease in toxicity poly-plat would al3pear to be an
alternative to cisplatin use. Many agents activate macrophages as well as cisplatin ;16.8). However,
there is no significant increase in Kupffer cell numbers recorded after administration of these
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agents. Poly-plat not only increases Kupffer cell activation, but also increases the number of
Kupffer cells present.
The staining pattern observed in light microscopy was the result of the non-specific
esterases found in the tissue. The mammalian liver has been shown to exhibit one of the highest
concentrations of these esterases compared to other or.clans, thus making esterase staining a
valuable tool for the observation of the various cell types 7). Non-specific esterases catalyze the
breakdown of ester bonds, which is a major mechanism of detoxification in the liver. Poly-plat
contains ester bonds. Currently it is not known if this drug is active in its natural or biotransformed
state. If ester hydrolysis is required for drug activation, then the normal levels of esterase found in
poly-plat treated hepatocytes may explain the increased immune system activation seen in Kupffer
cells after poly-plat administration as opposed to cisplatin.
The cisplatin treated liver revealed a three-fold increase in Kupffer cells over the control.
Self proliferation of Kupffer cells is impossible due to the inhibition of cell division in cisplatin
treated tissue (18), therefore the increase in numbers are solely the result of monocyte
differentiation. These Kupffer cells are more active in phagocytosing invader cells, due to their
increase in cytoplasmic extensions (6). These extensions have been shown to seek out and either
phagocytose invader cells, or transfer lysosomes down the extensions to lyse invaders (19). Poly-
plat does not inhibit cell division (15). The increase in Kupffer cell numbers, however, is too rapid to
be caused by macrophage proliferation. Therefore the increase in numbers must be caused by
monocyte differentiation as well. Rapidly dividing cells in the bone marrow which are unable to
divide during cisplatin treatment can readily produce an increase in circulating monocytes after
poly-plat administration, allowing for an even greater immune response over a period of time.
Cisplatin is able to activate peritoneal macrophages in vitro and cause lysis of the tumor
cells (4, 13). Poly-plat also has the capability to activate macrophages in vitro. Our study has shown
that poly-plat elicits much more macrophage activation, as depicted by extension formations,
lysosomal increases, TNF-cq IL-lo, iNOS, and N(2Oo,compared to cisplatin. Lysosomes take part in
tumor cell death through macrophage activation 21). A greater increase in lysosomes is seen in
poly-plat treated macrophages when compared to cisplatin treated macrophages. If lysosomal
activity is any indication of cytotoxicity than poly-plat may have greater efficacy in tumor cell death.
(22) TNF-o also plays a regulatory role in inflammation and immunological response to tumors
TNF-o activates production of nitric oxide which induces iron loss, and inhibits DNA synthesis,
mitochondrial respiration and the citric acid cycle
(23, 24).
IL-lo release by activated macrophages and its cyt0toxicity to tumor target cells proves it
as a potent mediator in tumor cell killing by macrophages (25). Its release in vitro occurs in a
cyclic manner showing its greatest increase at 2 h post-treatment after poly-plat. Compared to
cisplatin treatment, where the IL-lo release reaches a maximum only after 24 h. The iNOS is
induced by a variety of factors including endotoxins (eog. LPS) and cytokines [IL-lo, IFN-gamma
and TNF-o] (23). Results show that poly-plat increases iNOS well above levels reached by cisplatin.
NO released by primed macrophages mediates its cytotoxic effects through loss of iron (26),
(28) (27 29 30) inhibition of DNA synthesis, and mitochondrial respiration In addition, the reactive
oxygen species generated by macrophages could combine with NO to form substances that are
more potent than NO itself (31). NO combined with superoxides could yield peroxynitrite that
decomposes to hydroxide free radical and NO free radical. Our results demonstrate an immediate
increase in nitrite concentration in poly-plat treated macrophages after 30 mino in culture. These
processes may attribute to the cytotoxic ability of poly-plat primed macrophages inducing the
destruction of tumor cells.
Conclusion
Activated macrophages, efficient in phagocytosing invader cells, are effective scavengers
of invading organisms in the bloodstream due to their location in the sinusoid of the liver (Kupffer
cells) or in the peritoneal cavity (peritoneal macrophages)
(32, 33). Due to the increase in numbers
and cytoplasmic extensions, the macrophage populations are better equipped to deal with insult.
An increased understanding of the mechanisms controlling macrophage size and number can lead
to more effective treatment of distress. These results show that poly-plat is more effective than
cisplatin in macrophage activation, with less toxic side effects compared to cisplatin. Further
research is needed to determine the active state of poly-plat, and its relation to hepatocellular
esterase concentration, as well cytokine production.
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